Skip to main content
SpringerLink
Log in

Management of Antiphospholipid Syndrome in Pregnancy

  • Chapter
Hughes Syndrome

  • 778 Accesses

Summary

Pregnant women with APS are at risk of complications at all stages of pregnancy. They require specialist care and a team approach involving obstetricians, obstetric physicians, rheumatologists, hematologists, neonatologists, and specialist midwives. Close monitoring of the various aspects of the condition may reduce maternal morbidity and improve fetal outcome. Therapeutic options include aspirin, LMWH, and, less commonly, warfarin and steroids.

The pathogenesis of the adverse pregnancy outcome in APS has not yet been fully elucidated although there is active research in this field. Until this is ascertained, we must accept that many aspects of management are purely empirical and it is our duty to counsel women thoroughly such that they understand the risks and benefits of the treatment options they are offered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309–1311.

    Article  PubMed  CAS  Google Scholar 

  2. Stone S, Langford K, Nelson-Piercy C, Khamashta MA, Bewley S, Hunt BJ. Antiphospholipid antibodies do not a syndrome make. Lupus 2002;11:130–133.

    Article  PubMed  CAS  Google Scholar 

  3. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14:131–136.

    PubMed  CAS  Google Scholar 

  4. Ringrose DK. Anaesthesia and antiphospholipid syndrome — a review of 20 patients. Int J Obstet Anaesth 1997;6:107–111.

    Article  CAS  Google Scholar 

  5. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–763.

    Article  PubMed  CAS  Google Scholar 

  6. Julkunen H. Pregnancy in systemic lupus erythematosus. Contraception, fetal outcome and congenital heart block. Acta Obst Gynecol Scand 1994;73:517–520.

    Google Scholar 

  7. MacLean M, Cumming G, McCall F, Walker I, Walker J. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994;101:103–106.

    PubMed  CAS  Google Scholar 

  8. Silver RM, Branch DW. Recurrent miscarriage: autoimmune considerations. Clin Obstet Gynaecol 1994;37:745–760.

    CAS  Google Scholar 

  9. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301–3304.

    PubMed  CAS  Google Scholar 

  10. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity against sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993;168:206–210.

    PubMed  CAS  Google Scholar 

  11. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin in a general obstetric population. Am J Obstet Gynecol 1989;161:369–373.

    PubMed  CAS  Google Scholar 

  12. Perez MC, Wilson WA, Brown HL, Scopelitis E. Anti-cardiolipin antibodies in unselected pregnant women in relationship to fetal outcome. J Perinatol 1991;11:33–36.

    PubMed  CAS  Google Scholar 

  13. Branch DW, Scott JR, Kochenour NK. Obstetric complications associated with lupus anticoagulant. N Engl J Med 1985;313:1322–1326.

    Article  PubMed  CAS  Google Scholar 

  14. Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisolone suppression of maternal lupus anticoagulant. Lancet 1983;i:1361–1363.

    Article  Google Scholar 

  15. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolpin antibody test. Arch Intern Med 1986;146:2153–2156.

    Article  PubMed  CAS  Google Scholar 

  16. Reece EA, Garofalo J, Zheng XZ, Assimakopoulos E. Pregnancy outcome — influence of antiphospholipid antibody titer, prior pregnancy loss and treatment. J Reprod Med 1997;42:49–55.

    PubMed  CAS  Google Scholar 

  17. Lockwood CJ, Reece EA, Romero R, Hobbins JC. Antiphospholipid antibody and pregnancy wastage. Lancet 1986;2:742–743.

    Article  PubMed  CAS  Google Scholar 

  18. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994;120:470–475.

    PubMed  CAS  Google Scholar 

  19. Katano K, Aoki K, Ogasawara M, et al. Specific antiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera. Lupus 1995;4:304–308.

    PubMed  CAS  Google Scholar 

  20. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993;100:909–913.

    PubMed  CAS  Google Scholar 

  21. Buchanan NMM, Khamashta MA, Morton KE, Kerslake S, Baguley E, Hughes GRV. A study of 100 high risk lupus pregnancies. Am J Rep Immunol 1992;28:192–194.

    CAS  Google Scholar 

  22. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger JTA. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 1993;20:1152–1157.

    PubMed  CAS  Google Scholar 

  23. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe pre-eclampsia. Obstet Gynecol 1988;73:541–545.

    Google Scholar 

  24. Moodley J, Bhoola V, Duursma J, Pudifin D, Byrne S, Kenoyer DG. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. South African Med J 1995;85:105–107.

    CAS  Google Scholar 

  25. Yasuda M, Takakuwa K, Tanaka K. Studies on the association between the anticardiolipin antibody and pre-eclampsia. Acta Med Biol 1994;42:145–149.

    Google Scholar 

  26. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042–1048.

    Article  PubMed  CAS  Google Scholar 

  27. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995;86:555–559.

    PubMed  CAS  Google Scholar 

  28. Birdsall MA, Pattison NS, Chamley L. Antiphospholipid antibodies in pregnancy. Aust N Z J Obstet Gynecol 1992;32:328–330.

    CAS  Google Scholar 

  29. Kelly T, Whittle MJ, Smith DJ, Ryan G. Lupus anticoagulant and pregnancy. J Obstet Gynecol 1996;16:26–31.

    Google Scholar 

  30. Botet F, Romera G, Montagut P, Carmona F, Balasch J. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J Perinat Med 1997;25:192–196.

    Article  PubMed  CAS  Google Scholar 

  31. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management and controversies. Obstet Gynecol 2003;101:1333–1344.

    Article  PubMed  Google Scholar 

  32. Derksen RHWM, Khamashta MA, Branch DW. Management of obstetric antiphospholipid syndrome. Arthritis Rheum 2004;50:1028–1039.

    Article  PubMed  CAS  Google Scholar 

  33. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992;80:614–620.

    PubMed  CAS  Google Scholar 

  34. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997;6:509–513.

    PubMed  CAS  Google Scholar 

  35. Backos M, Rai R, Baxter N, Chilcott I T, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999;106:102–107.

    PubMed  CAS  Google Scholar 

  36. Huong DLT, Wechsler B, Blerty O, Vauthier-Brouzes D, Lefebvre G, Piette JC. A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 2001;28:2025–2030.

    PubMed  CAS  Google Scholar 

  37. Stone S, Hunt BJ, Khamashta MA, Bewley SJ, Nelson-Piercy C. Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in 35 women. Thromb Haemost 2004. In press.

    Google Scholar 

  38. Kerslake S, Morton KE, Versi E, et al. Early Doppler studies in lupus pregnancy. Am J Reprod Immunol 1992;28:172–175.

    PubMed  CAS  Google Scholar 

  39. Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L, Mancuso S. Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet Gynecol 1993;82:970–976.

    PubMed  CAS  Google Scholar 

  40. Venkat-Rahman N, Backos M, Teoh TG, Lo WT, Regan L. Uterine artery Doppler in predicting outcome in women with antiphospholipid syndrome. Obstet Gynecol 2001;98:235–242.

    Article  Google Scholar 

  41. Bats AS, Lejeune V, Cynober E, et al. Antiphospholipid syndrome and second or third trimester fetal death: follow-up in the next pregnancy. Eur J Obstet Reprod Biol 2004;114:125–129.

    Article  Google Scholar 

  42. Lin S, Shimizu I, Suehara N, Nakayama M, Aono T. Uterine artery velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995;85:760–765.

    Article  PubMed  CAS  Google Scholar 

  43. Cowchock FS. Autoantibodies and pregnancy loss. N Engl J Med 1997;337:197–198.

    Article  PubMed  CAS  Google Scholar 

  44. Empsom M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002;99:135–144.

    Article  Google Scholar 

  45. Elder MG, de Swiet M, Robertson A, Elder MA, Flloyd E, Hawkins DF. Low-dose aspirin in pregnancy. Lancet 1988;i:410.

    Article  Google Scholar 

  46. Silver R, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisolone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody positive obstetric patients. Am J Obstet Gynecol 1993;169:1411–1417.

    PubMed  CAS  Google Scholar 

  47. Balasch J, Carmona F, Lopez-Soto A, et al. Low-dose aspirin for prevention of pregnancy losses in women with antiphospholipid syndrome. Hum Reprod 1993;8:2234–2239.

    PubMed  CAS  Google Scholar 

  48. Krause I, Blank M, Gilbrut B, Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reprod Immunol 1993;29:155–161.

    PubMed  CAS  Google Scholar 

  49. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Am J Obstet Gynecol 1997;176:1099–1100.

    Article  PubMed  CAS  Google Scholar 

  50. Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks’ gestation. Ultrasound Obstet Gynecol 2003;22:233–239.

    Article  PubMed  CAS  Google Scholar 

  51. Lockshin MD. Which patients with antiphospholipid antibody should be treated and how? Rheum Dis Clin N Am 1993;19:235–247.

    CAS  Google Scholar 

  52. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomised trial comparing prednisolone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166:1318–1323.

    PubMed  CAS  Google Scholar 

  53. Ruffati A, Orsini A, Di Lenardo L, et al. A prospective study of 53 consecutive calcium heparin treated pregnancies in patients with antiphospholipid antibody-related fetal loss. Clin Exp Rheumatol 1997;15:499–505.

    Google Scholar 

  54. Ruffati A, Favoro M, Tonello M, et al. Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome. Lupus 2004. In press.

    Google Scholar 

  55. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss-treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584–1589.

    PubMed  CAS  Google Scholar 

  56. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997;314:253–257.

    CAS  Google Scholar 

  57. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408–413.

    Article  PubMed  CAS  Google Scholar 

  58. de Swiet M, Ward PD, Fidler J, et al. Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 1983;90:1129–1134.

    PubMed  Google Scholar 

  59. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993;168:1265–1270.

    PubMed  CAS  Google Scholar 

  60. Nelson-Piercy C, Letsky E, de Swiet M. Low molecular weight heparin for obstetric thromboprophylaxis: experience of 69 pregnancies in 61 high risk women. Am J Obstet Gynecol 1997;176:1062–1068.

    Article  PubMed  CAS  Google Scholar 

  61. Smith R, Stevenson JC, Winearls CG, Woods CG, Wordsworth BP. Osteoporosis of pregnancy. Lancet 1985;1:1178–1180.

    Article  PubMed  CAS  Google Scholar 

  62. Khastgir G, Studd J. Pregnancy-associated osteoporosis. Br J Obstet Gynaecol 1994;101:836–838.

    PubMed  CAS  Google Scholar 

  63. Smith R, Athanasou NA, Ostlere SJ, Vipond SE. Pregnancy-associated osteoporosis. QJM 1995;88:865–878.

    PubMed  CAS  Google Scholar 

  64. Nelson-Piercy C. Heparin-induced osteoporosis in pregnancy. Lupus 1997;6:500–504.

    PubMed  CAS  Google Scholar 

  65. Byrd LM, Johnston TA, Shiach C, Hay CRM. Osteopenic fractures and low molecular weight heparin in pregnancy. J Obstet Gynaecol 2004;24:S11.

    Article  Google Scholar 

  66. Greer IA, Nelson-Piercy C. Systematic review of safety and efficacy of LMWH in pregnancy. Br J Obstet Gynaecol 2004. In press.

    Google Scholar 

  67. Hunt BJ, Doughty H, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997;77:39–43.

    PubMed  CAS  Google Scholar 

  68. Hunt BJ, Gattens M, Khamashta M, Nelson-Piercy C, Almeida A. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinolysis 2003;14:735–739.

    Article  PubMed  CAS  Google Scholar 

  69. Nelson-Piercy C. Low molecular weight heparin for obstetric thromboprophylaxis. Br J Obstet Gynaecol 1994;101:6–8.

    PubMed  CAS  Google Scholar 

  70. Hunt BJ, Khamashta MA, Lakasing L, Williams F, Nelson-Piercy C, Hughes GRV. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable? Thromb Haemost 1998;79:1060–1061.

    PubMed  CAS  Google Scholar 

  71. Shaul WL, Hall JG. Multiple congenital anomalies associated with oral anticoagulants. Am J Obstet Gynecol 1977;127:191–198.

    PubMed  CAS  Google Scholar 

  72. Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197–203.

    PubMed  CAS  Google Scholar 

  73. Vitale N, Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999;33:1637–1641.

    Article  PubMed  CAS  Google Scholar 

  74. Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002;99:35–40.

    Article  PubMed  CAS  Google Scholar 

  75. Howe AM, Webster WS. Exposure of the pregnant rat to warfarin and vitamin K1: an animal model of intraventricular hemorrhage in the fetus. Teratology 1990;42:413–420.

    Article  PubMed  CAS  Google Scholar 

  76. Wellesley D, Moore I, Heard M, Keeton B. Two cases of warfarin embryopathy: a re-emergence of this condition? Br J Obstet Gynaecol 1998;105:805–806.

    PubMed  CAS  Google Scholar 

  77. Orme ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed their infants? Br Med J 1977;1:1564–1565.

    Article  PubMed  CAS  Google Scholar 

  78. McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? J Paediatr 1983;103:325–327.

    Article  CAS  Google Scholar 

  79. Kwak JYH, Barini R, Gilman-Sachs A, Beaman KD, Beer AE. Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome. Am J Obstet Gynecol 1994;171:239–246.

    PubMed  CAS  Google Scholar 

  80. Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisolone suppression of maternal lupus anticoagulant. Lancet 1983;i:1361–1363.

    Article  Google Scholar 

  81. Lockshin MD, Druzin ML, Qamar T. Prednisolone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynaecol 1989;160:439–443.

    CAS  Google Scholar 

  82. Laskin CA, Bombardier C, Hannah ME, et al. Prednisolone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;337:148–153.

    Article  PubMed  CAS  Google Scholar 

  83. Spinnato JA, Clark AL, Pierangeli SS, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995;172:690–694.

    Article  PubMed  CAS  Google Scholar 

  84. Kaaja R, Julkunen H, Ammala P, Palouso T, Kurki P. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynaecol Scand 1993;72:63–66.

    CAS  Google Scholar 

  85. Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, Van Assche A, Vermylen J. High-dose intravenous immunoglobulin in a pregnant patient with antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost 1994;71:741–747.

    PubMed  CAS  Google Scholar 

  86. Fulcher D, Stewart G, Exne T, Trudinger B, Jeremy R. Plasma exchange and the anticardiolipin syndrome in pregnancy. Lancet 1989;ii:171.

    Article  Google Scholar 

  87. Fishman P, Falach Vaknine E, Zigelman R, et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993;21:1834–1837.

    Google Scholar 

  88. Gordon C, Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus 1998;7:429–433.

    Article  PubMed  CAS  Google Scholar 

  89. Gordon C, Raine-Fenning N, Brackley K, Bacon PA, Weaver J, Kilby M. Intravenous immunoglobulin (IVIG) therapy to salvage severely compromised pregnancies in SLE and antiphospholipid (aPL) syndrome. Lupus 1998;7:114.

    Article  Google Scholar 

  90. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent pregnancy loss associated with antiphospholipid antibodies. Arthritis Rheum 2003;48:728–731.

    Article  PubMed  CAS  Google Scholar 

  91. Royal College of Obstetricians and Gynaecologists. Thromboprophylaxis during pregnancy, labour and after vaginal delivery, 2004 Guidelines. London: Royal College of Obstetricians and Gynaecologists, 2004.

    Google Scholar 

  92. Branch DW. Thoughts on the mechanism of pregnancy loss associated with the antiphospholipid syndrome. Lupus 1994;3:275–280.

    PubMed  CAS  Google Scholar 

  93. Lakasing L, Poston L. Adverse pregnancy outcome in antiphospholipid syndrome: focus for future research. Lupus 1997;6:1–4.

    Google Scholar 

  94. Di Simone N, Del Papa N, Raschi E, et al. Antiphospholipid antibodies affect trophoblast gonadotrophin secretion and invasiveness by binding directly and through adhered β2-glycoprotein I. Arthritis Rheum 2000;43:140–150.

    Article  PubMed  Google Scholar 

  95. Di Simone N, Caliandro D, Castellani R, Ferrazzani S, Caruso A. Interleukin-3 and human trophoblast: in vitro explanations for the effect of interleukin in patients with antiphospholipid antibody syndrome. Fertil Steril 2000;73:1194–1200.

    Article  PubMed  Google Scholar 

  96. Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999;14:489–495.

    Article  PubMed  Google Scholar 

  97. Lala PK, Hamilton GS. Growth factors, proteases and protease inhibitors in the maternal-fetal dialogue. Placenta 1996;17:545–555.

    Article  PubMed  CAS  Google Scholar 

  98. McMaster MT, Bass KE, Fisher SJ. Human trophoblast invasion, autocrine control and paracrine modulation. Ann N Y Acad Sci 1994;734:122–131.

    PubMed  CAS  Google Scholar 

  99. Guilbert L, Robertson SA, Wegmann TG. The trophoblast as an integral component of a macrophage-cytokine network. Immunol Cell Biol 1993;71:49–57.

    PubMed  CAS  Google Scholar 

  100. Burrows TD, King A, Loke YW. Trophoblast migration during human placental implantation. Hum Reprod Update 1996;2:307–321.

    Article  PubMed  CAS  Google Scholar 

  101. Fisher SJ, Damsky CH. Human cytotrophoblast invasion. Sem Cell Biol 1993;4:183–188.

    Article  CAS  Google Scholar 

  102. Vicovac L, Aplin JD. Epithelial-mesenchymal transition during trophoblast differentiation. Acta Anatomica 1996;156:202–216.

    Article  PubMed  CAS  Google Scholar 

  103. Aplin JD. The cell biology of human implantation. Placenta 1996;17:269–275.

    Article  PubMed  CAS  Google Scholar 

  104. McMaster MT, Librach CL, Zhou K, et al. Expression Is restricted to differentiated cytotrophoblasts. J Immunol 1995;154:3771–3778.

    PubMed  CAS  Google Scholar 

  105. Vogt E, Ah-Kau N, Rote NS. A model for the antiphospholipid antibody syndrome: monoclonal antiphosphotidylserine antibody induces intrauterine growth restriction in mice. Am J Obstet Gynecol 1996;174:700–707.

    Article  PubMed  CAS  Google Scholar 

  106. Silver RM, Smith LA, Edwin SS, Oshiro BT, Branch DW. Variable effects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies. Am J Obstet Gynecol 1997;177:229–233.

    Article  PubMed  CAS  Google Scholar 

  107. Horkko S, Miller E, Dudl E, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996;98:815–825.

    Article  PubMed  CAS  Google Scholar 

  108. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994;84:2854–2867.

    PubMed  CAS  Google Scholar 

  109. Lockwood CJ, Rand JH. The immunology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surg 1994;49:432–441.

    CAS  Google Scholar 

  110. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544–1547.

    Article  PubMed  CAS  Google Scholar 

  111. Fleck RA, Rapaport SI, Rao L. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988;72:512–519.

    PubMed  CAS  Google Scholar 

  112. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982;142:829–834.

    PubMed  Google Scholar 

  113. Erlendsson K, Steinsson K, Johannsson JH, Geirsson RT. Relation of antiphospholipid antibody and placental bed inflammatory vascular changes to the outcome of pregnancy in successive pregnancies of 2 women with systemic lupus erythematosus. J Rheumatol 1993;20:1779–1785.

    PubMed  CAS  Google Scholar 

  114. Labarrere CA, Faulk WP. Fetal stem vessel endothelial changes in placentae from normal and abnormal pregnancies. Am J Reprod Immunol 1992;27:97–100.

    PubMed  CAS  Google Scholar 

  115. Rand JH, Wu XX, Guller S, Gil G, Scher J, Lockwood CJ. Reduction of annexin V (placental anticoagulant protein-1) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994;171:1566–1572.

    PubMed  CAS  Google Scholar 

  116. Rand JH, Wu XX, Andree HAM, et al. Pregnancy loss in the antiphospholipid-antibody syndrome — a possible thrombogenic mechanism. N Engl J Med 1997;337:154–160.

    Article  PubMed  CAS  Google Scholar 

  117. La Rosa L, Meroni PL, Tinicani A, et al. β2glycoprotein-I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J Rheumatol 1994;21:1684–1693.

    PubMed  Google Scholar 

  118. Lakasing L, Campa JS, Poston R, Khamashta MA, Poston L. Normal expression of tissue factor, thrombomodulin and annexin V in placentas from women with antiphospholipid syndrome, Am J Obstet Gynecol 1999;181:180–189.

    Article  PubMed  CAS  Google Scholar 

  119. Lyall F, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod 1996;1:107–116.

    Article  PubMed  CAS  Google Scholar 

  120. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003;109:73–81.

    Article  PubMed  CAS  Google Scholar 

  121. Brenner B. Clinical management of thrombophilia related placental vascular complications. Blood 2004;103:4003–4009.

    Article  PubMed  CAS  Google Scholar 

  122. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644–1654.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics, Guy’s and St. Thomas’ Hospitals NHS Trust, London, UK

    Lorin Lakasing MD, MRCOG, Susan Bewley MBBS, MA, MD & Catherine Nelson-Piercy MBBS, MA, FRCP

Authors
  1. Lorin Lakasing MD, MRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Bewley MBBS, MA, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Nelson-Piercy MBBS, MA, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lupus Research Unit, St Thomas’ Hospital, London, UK

    M. A. Khamashta MD, FRCP, PhD (Deputy Head) (Deputy Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Lakasing, L., Bewley, S., Nelson-Piercy, C. (2006). Management of Antiphospholipid Syndrome in Pregnancy. In: Khamashta, M.A. (eds) Hughes Syndrome. Springer, London. https://doi.org/10.1007/1-84628-009-5_44

Download citation

  • DOI: https://doi.org/10.1007/1-84628-009-5_44

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-873-2

  • Online ISBN: 978-1-84628-009-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation